Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, Morii S
Department of Pathology, Kansai Medical University, Osaka, Japan.
J Surg Res. 1993 Sep;55(3):295-7. doi: 10.1006/jsre.1993.1143.
Tenascin immunohistochemical staining was investigated in 82 patients with primary invasive breast carcinoma followed for at least 5 years after surgery; the staining was analyzed in relation to clinicopathological factors. An intense tenascin staining pattern was noted in 59 patients (72%), but no definite correlation was found between tenascin positivity and clinical stage, lymph node metastasis, or estrogen receptor status. However, tenascin-positive patients had a significantly better prognosis than tenascin-negative patients. Tenascin staining may therefore be a useful marker for predicting the survival of breast cancer patients.
对82例原发性浸润性乳腺癌患者进行了腱生蛋白免疫组化染色研究，这些患者术后至少随访了5年；分析了该染色与临床病理因素的关系。59例患者（72%）呈现强烈的腱生蛋白染色模式，但未发现腱生蛋白阳性与临床分期、淋巴结转移或雌激素受体状态之间存在明确关联。然而，腱生蛋白阳性患者的预后明显优于腱生蛋白阴性患者。因此，腱生蛋白染色可能是预测乳腺癌患者生存情况的有用标志物。
